Erdogan-Trinkaus Ipek

Chief Commercial Officer

Erdogan-Trinkaus Ipek has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Nov 12, 2026.

On the most recent filing, Erdogan-Trinkaus Ipek is listed as Chief Commercial Officer at Eton Pharmaceuticals, Inc. Inside the rolling window, Erdogan-Trinkaus Ipek reported no open-market purchases and 1 open-market sale totaling $236K in ETON.

Companies traded

Other insiders at ETON

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$236K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ETONSale$236KNov 12SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Erdogan-Trinkaus Ipek made?

Erdogan-Trinkaus Ipek has filed 2 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.

Which companies does Erdogan-Trinkaus Ipek trade?

Erdogan-Trinkaus Ipek has filed SEC Form 4 disclosures for 1 company, including ETON.

When was Erdogan-Trinkaus Ipek's most recent SEC Form 4 filing?

Erdogan-Trinkaus Ipek's most recent SEC Form 4 filing on Tracefour is dated Nov 12, 2026.

What is Erdogan-Trinkaus Ipek's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Erdogan-Trinkaus Ipek is listed as Chief Commercial Officer.

What is Erdogan-Trinkaus Ipek's total buy and sell value in the current window?

Inside the rolling retention window, Erdogan-Trinkaus Ipek bought $0 and sold $236K based on SEC Form 4 filings.

What was Erdogan-Trinkaus Ipek's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 3,500 ETON shares on 2026-11-10, worth $236K, per SEC Form 4 filings.